Ironwood Rises as AbbVie’s Linzess Sales Beat Expectations
Ironwood shares climb after AbbVie reports strong Q3 Linzess sales of $315M, surpassing estimates and boosting investor confidence.
/ 11 items
#ABBV↓
H.C. Wainwright Rates Zymeworks a Buy on Promising ZW191 Cancer Drug Data
H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.
Gilead's Biktarvy Patent Extended to 2036
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Amneal's Generic Bimatoprost Ophthalmic Solution Approved by FDA
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.
AbbVie's Rinvoq Gets a Big Win: Generics Delayed Until 2037!
AbbVie secured a "big win," delaying generic Rinvoq until April 2037 by settling lawsuits. This extends the drug's market run significantly, much longer than expected, boosting company value and helping offset declining Humira sales.